How Do Tysabri-Associated PML Symptoms Compare to Other MS Therapy Risks?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational Safety

If you or a loved one is taking Tysabri for multiple sclerosis, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). Recognizing how PML symptoms differ from typical MS flare-ups can be critical for early detection. Building on decades of pharmacovigilance research, this page compares the clinical signals of Tysabri-associated PML with those of other disease-modifying therapies, helping you understand what to watch for.

Medical Evidence: Tysabri and PML Risk

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically only occurs in patients who are immunocompromised, and it has occurred in patients who have received Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation and diagnosis of PML involve progressive neurological deficits such as cognitive impairment, motor weakness, gait disturbance, and visual changes. The diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid. Early recognition is critical because PML can rapidly progress to severe disability or death. Tysabri's pharmacology involves binding to alpha-4 integrins on leukocytes, preventing their migration across the blood-brain barrier. This reduces inflammatory activity in the central nervous system but also impairs immune surveillance against JCV. The mechanistic pathway linking Tysabri to PML involves reduced trafficking of JCV-specific T cells into the brain, allowing latent JCV to reactivate and cause lytic infection of oligodendrocytes. Three factors are known to increase the risk of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration especially beyond 2 years, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients who received Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Two cases were observed in the 1869 patients with multiple sclerosis who were treated for a median of 120 weeks; these two patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of the 1043 patients with Crohn's disease who were evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). FDA FAERS adverse-event reports most frequently associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, and balance disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These reports reflect the underlying disease and potential adverse effects, but PML is a distinct and severe complication. Healthcare professionals should monitor patients on Tysabri for any new sign or symptom that may be suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Legal Context and North Carolina Considerations

The adequacy of warnings regarding Tysabri and PML is a central concern. The boxed warning clearly states the increased risk and identifies risk factors. However, patients and healthcare providers must weigh these risks against the benefits of treatment. For affected patients, attorney-related considerations may include evaluating whether the warnings were adequately communicated and whether the patient's specific risk factors were properly assessed before and during treatment. The timeline between exposure and documented harm can vary. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability underscores the need for ongoing monitoring. Patients who develop PML after Tysabri treatment may face severe disability or death. Legal considerations for affected individuals in North Carolina may involve consulting with an attorney experienced in pharmaceutical injury cases. Such attorneys can help assess whether the manufacturer provided adequate warnings and whether the patient's medical team followed appropriate monitoring protocols. The restricted distribution program aims to mitigate risk, but cases of PML continue to occur, highlighting the importance of vigilance. In summary, Tysabri is associated with a known risk of PML, which is a serious and often fatal brain infection. The prescribing information provides clear warnings and identifies risk factors. Healthcare professionals must monitor patients closely and withhold Tysabri at the first sign of PML. Patients and their families should be aware of the symptoms and seek immediate medical attention if they occur. For those affected, legal counsel may provide guidance on potential claims related to inadequate warnings or failure to monitor.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and what is its association with PML?

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. It carries a boxed warning stating that it increases the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the JC virus that often leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three factors increase the risk: presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How is PML diagnosed and what are its symptoms?

PML presents with progressive neurological deficits such as cognitive impairment, motor weakness, gait disturbance, and visual changes. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid. Early recognition is critical as PML can rapidly progress to severe disability or death.

What legal options are available for individuals in North Carolina who developed PML after Tysabri?

Affected individuals may consult with an attorney experienced in pharmaceutical injury cases to assess whether the manufacturer provided adequate warnings and whether proper monitoring protocols were followed. Legal counsel can provide guidance on potential claims related to inadequate warnings or failure to monitor.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.